Ovarian cancer (OC) is one of the most threatening malignant tumors in females due to the frequent occurrence of metastasis that precedes diagnosis. The prevention and treatment of OC metastasis continues to provide a significant molecular challenge. To develop new anti-metastatic therapies, we need to understand the biological and biochemical mechanisms of metastasis. Although many genetic events promote metastasis, several genes show relatively reduced expression levels in metastatic tumor cells. Re- expression of a metastasis-suppressor gene in metastatic tumor results in a significant reduction in metastatic behavior in vivo. The cellular functions of a metastasis suppressor gene, NM23-H2 are not known in ovarian cancer. Recently, we have demonstrated a) reduced expression of NM23-H2 in ovarian cancer (OVCA) cell lines compared to normal human ovarian surface epithelial (HOSE) cell lines, b) increased transcription of NM23-H2 in epithelial OVCA cells when treated with progesterone and c) marked decrease in cell invasiveness when NM23-H2 was re-expressed in OVCA cells. Based on these preliminary data, we hypothesize that down regulation of NM23 gene is involved in the pathogenesis of epithelial OC and elevation of metastasis suppressor gene expression in tumor cells will halt metastatic colonization and have a clinical benefit.
Two aims have been put forth to test the hypothesis:
Specific Aim 1 : Determination of the NM23-H2 protein in a variety of ovarian cancer tissue sections and correlation of its expression with the stage of disease.
Specific Aim 2 : To determine 1) Whether NM23-H2 re-expression will decrease invasive behavior of OVCA cells in vitro and in vivo and 2) To establish whether progesterone injections will decrease metastasis potential of OVCA cells by up-regulating NM23-H2 expression in vivo. Reactivation of NM23-H2 gene may yield a potential therapeutic intervention for ovarian cancer. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Research Grants (R03)
Project #
7R03CA123558-03
Application #
7555546
Study Section
Special Emphasis Panel (ZCA1-SRRB-Q (M1))
Program Officer
Patriotis, Christos F
Project Start
2006-08-01
Project End
2010-07-31
Budget Start
2008-03-14
Budget End
2010-07-31
Support Year
3
Fiscal Year
2007
Total Cost
$74,718
Indirect Cost
Name
Henry M. Jackson Fdn for the Adv Mil/Med
Department
Type
DUNS #
144676566
City
Bethesda
State
MD
Country
United States
Zip Code
20817
Al-Hassan, Nada N; Behzadian, Ali; Caldwell, Ruth et al. (2012) Differential roles of uPAR in peritoneal ovarian carcinomatosis. Neoplasia 14:259-70
Nguyen, Huyen; Ivanova, Vessela S; Kavandi, Leyla et al. (2011) Progesterone and 1,25-dihydroxyvitamin D? inhibit endometrial cancer cell growth by upregulating semaphorin 3B and semaphorin 3F. Mol Cancer Res 9:1479-92
Joseph, Doina; Ho, Shuk-Mei; Syed, Viqar (2010) Hormonal regulation and distinct functions of semaphorin-3B and semaphorin-3F in ovarian cancer. Mol Cancer Ther 9:499-509
Syed, Viqar; Mukherjee, Kasturi; Godoy-Tundidor, Sonia et al. (2007) Progesterone induces apoptosis in TRAIL-resistant ovarian cancer cells by circumventing c-FLIPL overexpression. J Cell Biochem 102:442-52